Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 167

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Open access
Recondo, Gonzalo, Mezquita, Laura, Facchinetti, Francesco, Planchard, David, Gazzah, Anas, Bigot, Ludovic, Rizvi, Ahsan Z., Frias, Rosa L., Thiery, Jean Paul, Scoazec, Jean-Yves, Sourisseau, Tony, Howarth, Karen, Deas, Olivier, Samofalova, Dariia, Galissant, Justine, Tesson, Pauline, Braye, Floriane, Naltet, Charles, Lavaud, Pernelle, Mahjoubi, Linda, Abou Lovergne, Aurélie, Vassal, Gilles, Bahleda, Rastilav, Hollebecque, Antoine, Nicotra, Claudio, Ngo-Camus, Maud, Michiels, Stefan, Lacroix, Ludovic, Richon, Catherine, Auger, Nathalie, De Baere, Thierry, Tselikas, Lambros, Solary, Eric, Angevin, Eric, Eggermont, Alexander M., Andre, Fabrice, Massard, Christophe, Olaussen, Ken A., Soria, Jean-Charles, Besse, Benjamin, Friboulet, Luc · 2020 · Clinical Cancer Research

Abstract

Purpose: Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with first- and second-generation ALK inhibitors. Beside compound mutations in the ALK kinase domain, other resistance mechanisms driving lorlatinib resistance remain unknown. We aimed to characterize the mechanisms of resistance to lorlatinib occurring in patients with ALK-rearranged lung cancer and design new therapeutic strategies in this setting. Experimental Design: Resistance mechanisms were investigated in 5 patients resistant to lorlatinib. Longitudinal tumor biopsies were studied using high-throughput next-generation sequencing. Patient-derived models were developed to characterize the acquired resistance mechanisms, and Ba/F3 cell mutants were generated to study the effect of novel ALK compound mutations. Drug combinatory strategies were evaluated in vitro and in vivo to overcome lorlatinib resistance. Results: Diverse biological mechanisms leading to lorlatinib resistance were identified. Epithelial–mesenchymal transition (EMT) mediated resistance in two patient-derived cell lines and was susceptible to dual SRC and ALK inhibition. We characterized three ALK kinase domain compound mutations occurring in patients, L1196M/D1203N, F1174L/G1202R, and C1156Y/G1269A, with differential susceptibility to ALK inhibition by lorlatinib. We identified a novel bypass mechanism of resistance caused by NF2 loss-of-function mutations, conferring sensitivity to treatment with mTOR inhibitors. Conclusions: This study shows that mechanisms of resistance to lorlatinib are diverse and complex, requiring new therapeutic strategies to tailor treatment upon disease progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-1104

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 167

Metadata

Authors
Recondo, G., Mezquita, L., Facchinetti, F., Planchard, D., Gazzah, A., Bigot, L., Rizvi, A. Z., Frias, R. L., Thiery, J. P., Scoazec, J.-Y., Sourisseau, T., Howarth, K., Deas, O., Samofalova, D., Galissant, J., Tesson, P., Braye, F., Naltet, C., Lavaud, P., Mahjoubi, L., Abou Lovergne, A., Vassal, G., Bahleda, R., Hollebecque, A., Nicotra, C., Ngo-Camus, M., Michiels, S., Lacroix, L., Richon, C., Auger, N., De Baere, T., Tselikas, L., Solary, E., Angevin, E., Eggermont, A. M., Andre, F., Massard, C., Olaussen, K. A., Soria, J.-C., Besse, B., & Friboulet, L.
Venue
Clinical Cancer Research
Published
2020-01-01
Volume
26
Issue
1
Pages
242-255
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2978074062
Cited by
167
References
6
FWCI
14.17
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1104
The paper
Recondo, G., Mezquita, L., Facchinetti, F., Planchard, D., Gazzah, A., Bigot, L., Rizvi, A. Z., Frias, R. L., Thiery, J. P., Scoazec, J.-Y., Sourisseau, T., Howarth, K., Deas, O., Samofalova, D., Galissant, J., Tesson, P., Braye, F., Naltet, C., Lavaud, P., . . . Friboulet, L. (2020). Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1104

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.